DexCom vs MiniMed
DXCM and MMED side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DXCM and MMED compare
DexCom is the larger company, worth 6.0 times as much as MiniMed ($31.1B against $5.1B).
MiniMed grew revenue faster over the last twelve months (14.3% versus 13.0% for DexCom).
DexCom keeps more of each dollar of sales as profit, with a net margin of 19.4% compared with −10.7% at MiniMed.
DexCom scores higher on the StockData Score (22 against 13 for MiniMed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DXCM | MMED |
|---|---|---|
| Size and price | ||
| Market cap | $31.1B | $5.1B |
| Share price | $82.29 | $18.28 |
| Change, 1 year | 20.7% | – |
| Change, 5 years | −48.2% | – |
| Beta (5Y) | 1.20 | – |
| Employees | 11K | 8,000 |
| StockData Score | ||
| Total score | 22 (better) | 13 |
| Valuation score | 4 (better) | 3 |
| Growth score | 6 (better) | 2 |
| Performance score | 6 (better) | 2 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.4× | – |
| P/S | 6.1× | 1.7× (better) |
| P/B | 12.2× | 1.4× (better) |
| EV/EBITDA | 20.1× | – |
| P/FCF | 28.3× | – |
| PEG | 0.89 | – |
| FCF yield | 3.5% (better) | −8.2% |
| Fair value | $117.75 | $35.17 |
| Margin of safety | 30.1% | 48.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.0% | 14.3% (better) |
| Revenue growth, 5Y average | 19.3% | – |
| Net income growth (TTM) | 37.5% | – |
| EPS growth (TTM) | 41.9% | – |
| EPS growth, 5Y average | 9.5% | – |
| Profitability | ||
| Gross margin | 63.4% (better) | 54.2% |
| Operating margin | 24.0% (better) | −6.1% |
| Net margin | 19.4% (better) | −10.7% |
| FCF margin | 21.5% (better) | −13.5% |
| Return on equity | 37.7% (better) | −9.6% |
| Return on invested capital | 78.0% (better) | −4.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | 91.3× | – |
| Current ratio | 1.74 | 1.81 (better) |
| Altman Z-score | 7.53 (better) | 3.46 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.08% | – |
| Shareholder yield | −0.08% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 102% | 13.2% |
| Held by insiders | 0.52% | 90.6% |
| Insider net buying, 12 months | −$11.6M | – |
| Short interest, % of float | 3.7% | – |
Go deeper
- DXCM stock overview
- DXCM income statement
- DXCM valuation and score
- MMED stock overview
- MMED income statement
- MMED valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.